About this video

• Video Title: Avoid These Peptides for 2026 (Doctor Reveals Peptides to Avoid)
• Channel: Dr. Jones, DC
• Speakers: Dr. Jones
• Duration: 17:01

Overview

This video provides guidance on which peptides to avoid and which to use with caution for optimal health outcomes in 2026. Dr. Jones categorizes peptides into two tiers: those to be avoided entirely and those requiring careful consideration. He discusses the potential risks associated with various peptides, emphasizing the importance of proper sourcing, dosage, and professional supervision to prevent adverse effects.

Key takeaways

• Tier 1: Peptides to Avoid Entirely: This category includes unregulated oral BPC-157 (specifically from Amazon or research sites), CJC-1295 with DAC, MK-677, and aggressive GHRP stacks like hexarelin. These peptides are deemed problematic due to issues with sourcing, lack of regulation, potential for adverse metabolic effects, and the risks associated with combining multiple compounds.
• Tier 2: Peptides to Use With Caution: Peptides in this tier, such as IGF-1 analogs (LR3 and DES), Epitalon, and FOXO4-DR1, are not necessarily dangerous but carry a risk-to-benefit ratio that may not be favorable for most individuals. Their use requires careful consideration due to potential long-term effects, limited conclusive research, or the possibility of unintended consequences.
• Three Ways Peptides Can Harm You: Peptides can cause harm through bad molecules (inherent problems with the compound), bad sources (contamination, mislabeling), or bad protocols (incorrect dosage, combinations, or lack of supervision).
• Importance of Professional Guidance: The video stresses the critical need for clinician supervision, proper testing, and understanding peptide interactions to ensure safe and effective use, especially when stacking multiple compounds.